

CHARTTRENDS®: MULTIPLE SCLEROSIS IN THE EU

BioTrends Research Group is pleased to announce the continuation of **ChartTrends®: Multiple Sclerosis in the EU** in 2012. In this report, patient level data are captured from 1000+ unique multiple sclerosis (MS) patient records. These patient audits are completed by 225+ neurologists who submit between four and seven audits each. Respondents are limited to one patient per disease-modifying agent (DMA) brand (Avonex, Betaferon, Copaxone, Extavia, Gilenya, Rebif and Tysabri) and each patient must be on at least their second-line DMA to allow for treatment flow analysis. At least 150 charts from most brands (newer DMAs may be an exception) are included in the audit, allowing for comparisons between brands.

ChartTrends are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product initiation, switching, concomitant medications,

SAMPLE FRAME AND METHODOLOGY

More than 225 neurologists from the UK (n=25+), Germany (n=50+), France (n=50+), Spain (n=50+), and Italy (n=50+) will complete patient audits for between four and seven of their MS patients currently being treated with a DMA. Each patient audit took approximately 15-20 minutes to complete

To qualify for participation, neurologists must meet the following criteria:

- In practice between 2 and 30 years
- Must have at least 50 patients with MS under management

Each patient record meets the following criteria:

- At least 18 years of age
- On commercially available DMA therapy for at least the past 6 months
- On second-line or later of DMA therapy
- Only one patient per brand, per neurologist may be reviewed

All methods are compliant with local patient privacy laws

In addition to completing the patient audit, each neurologist completes a profile survey regarding attitudes, perceptions, and treatment practices

RELATED 2012 REPORTS

TreatmentTrends®: Multiple Sclerosis (US)
TreatmentTrends®: Multiple Sclerosis (EU)
ChartTrends®: Multiple Sclerosis (US)
PatientTrends: Multiple Sclerosis
Treatment Algorithms: Multiple Sclerosis
LaunchTrends®: Aubagio
LaunchTrends®: Lemtrada
Special Report: Impact of the Anti-JC Virus Antibody Assay

PRICE

\$80,000

PROJECT OBJECTIVES


- Quantify MS patient load and distribution by disease classification
 - Understand the demographics of MS patients including diagnosis, comorbidities, exacerbations, and time followed
- Quantify the treatment paradigm for the chronic management of MS and treatment of exacerbations
 - Identify the factors that drive the decision to initiate DMA therapy in DMA-naïve patients, DMA discontinuation, and current DMA selection
- Understand the standard of care for MS patients
 - Use and frequency of laboratory and MRI assessments; laboratory values and MRI results
- Develop patient profiles for each of the current DMAs
 - Understand initiation, switching, monitoring, and discontinuation of DMAs
- Evaluate physician receptivity to late stage DMAs in development for the treatment of MS
 - Identify patient types and which DMAs are at risk of being displaced by these products
- Understand how neurologists approach the management of MS-related symptoms
 - Identify patient profile of patients prescribed Sativex
- Each of the above metrics maybe analyzed by EU5 country or by specific DMA brand

DELIVERABLES

- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics, and cross tabulations
- Database containing de-identified patient audit data in SPSS and/or Excel
- Proprietary question slide deck and frequency tables
 - Clients purchasing prior to fielding had the opportunity to include up to three proprietary questions in the physician profile section

REPORT DATES


Date comments/proprietary questions are due	Field date	Publication date
February 28, 2012	March 23, 2012	May 25, 2012



CHARTTRENDS®: MULTIPLE SCLEROSIS IN THE EU

TABLE OF CONTENTS


- Project Overview..... 4
- Executive Summary..... 15
- Physician Demographics (Self-Reported)..... 22
 - Physician Demographics
 - DMA Class Share by MS Disease Classification
 - DMA Brand Allocation
 - Chemotherapeutic / Immunosuppressant Prevalence by Disease Classification
 - DMA Line of Therapy
 - Most Likely Initiation of DMA by Patient Type
 - Mean Exacerbation by DMA Brand
 - Attribute Importance
 - Sativex Use
 - DMA Statement Agreement
 - Aided Awareness of DMAs in Development
 - Anticipated Use of DMAs in Development Among RRMS Patients
- MS Patient Demographics..... 38
 - Disease Classification
 - Age Distribution
 - Gender and Pregnancy History
 - Body Mass Index
 - Ethnicity
 - Employment/Economic Status
 - Referral Source / Reason
 - Length of Patient Care
 - Office Visit
 - Comorbidities
 - Patient Referrals Out
 - Timing First Diagnosed with MS
 - Timing Since First Treated with DMA
 - Most Recent Test Results (MRI, VEP, BAER, SEP, EDSS, T25FW)
 - Most Recent Lab Results (CSF, WBC, hemoglobin, hematocrit, creatinine, CrCL, ALT, AST, JC virus)
- First Line DMA Brand Comparison..... 58
 - Reasons for DMA Initiation
 - DMA Line of Therapy
 - First Line by Country
 - DMA-Naïve Patient Starts
 - Reasons for DMA Therapy Initiation by First Line Brand
 - MRI Monitoring at DMA Therapy Initiation
 - Time Lapse Before DMA Initiation by First Line Brand
 - Switching Following First Line DMA
 - Second Line DMA by Country



CHARTTRENDS®: MULTIPLE SCLEROSIS IN THE EU

TABLE OF CONTENTS


▪Current DMA Brand Comparison.....	69
▪ Reasons for Current DMA Brand Initiation	
▪ DAM-Naïve Patient Starts by Current Brand	
▪ Age Distribution by Current Brand	
▪ Gender and Pregnancy History by Current Brand	
▪ BMI by Current Brand	
▪ Economic Status by Current Brand	
▪ Employment Status by Current Brand	
▪ Length of Current DMA Treatment	
▪ Most Recent Exacerbations (symptoms, time since, severity, impact on work, healthcare burden, treatment, etc)	
▪ Exacerbation Progression on Current Brand	
▪ MRI Progression by Current Brand	
▪ CNS Lesions Progression by Current Brand	
▪ Brain Volume Change by Current Brand	
▪ Current Disease Progression by Current Brand	
▪ Quality of Life by Current Brand	
▪ Disability by Current Brand	
▪ Employment-Related Activities Impact by Current Brand	
▪ Number of Hospitalizations	
▪ Reasons for Most Recent Hospitalization	
▪ Medical Instruction Adherence by Current Brand	
▪ Satisfaction with Clinical Response by Current Brand	
▪ Next Steps After Poor Clinical Response	
▪ Reasons for DMA Discontinuation	
▪The Avonex-Treated MS Patient Profile.....	115
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Reasons for Discontinuation	
▪The Betaferon-Treated MS Patient Profile.....	121
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Reasons for Discontinuation	



CHARTRENDS®: MULTIPLE SCLEROSIS IN THE EU

TABLE OF CONTENTS

▪The Copaxone-Treated MS Patient Profile.....	127
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Reasons for Discontinuation	
▪The Extavia-Treated MS Patient Profile.....	133
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Reasons for Discontinuation	
▪The Rebif-Treated MS Patient Profile.....	139
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Dosing	
▪ Reasons for Discontinuation	
▪The Tysabri-Treated MS Patient Profile.....	146
▪ Patient Profile Summary	
▪ Origination	
▪ Reasons for Initiation	
▪ Switching	
▪ Reasons for Discontinuation	
▪Current MS-Related Symptoms.....	152
▪ Current Symptoms	
▪ Depression / Apathy Management	
▪ Acute or Chronic Pain Syndrome Management	
▪ Spasticity Management	
▪ Bladder / Bowel Dysfunction Management	
▪ Other symptoms available in appendix	
▪Symptomatic Management (Sativex).....	158
▪ Treatment Aims of Sativex Use	
▪ Reasons for Sativex Initiation	
▪ Timing of Initial Prescription	
▪ Dosing Frequency	
▪ Patient Discontinuation	



CHARTTRENDS®: MULTIPLE SCLEROSIS IN THE EU

TABLE OF CONTENTS

▪DMAs in Development.....	164
▪ Aided Familiarity of DMAs in Development	
▪ DMAs in Development That Audited Patients Would be Most Likely Switched To	
▪ Reasons for Choosing DMA in Development	
▪ Potential Market Opportunity: Self-Reported Versus Audited Share	
▪ Anticipated DMA Replacement by DMAs in Development	
▪ Anticipated Gilenya Patient Profile	
▪ Anticipated PEG-Avonex Patient Profile	
▪ Anticipated Laquinimod Patient Profile	
▪ Anticipated BG-12 Patient Profile	
▪ Anticipated Alemtuzumab Patient Profile	
▪ Anticipated Teriflunomide Patient Profile	
▪ Anticipated Daclizumab Patient Profile	
▪ Anticipated Ocrelizumab Patient Profile	
▪Appendix.....	183